Coventry biotech Ovo Biomanufacturing secures £229.6k to optimize vaccine production

Ovo Biomanufacturing Ltd has raised an estimated £229.6k to further develop its technology for viral vaccine and gene therapy manufacturers. Based in Coventry, the company provides a software based platform and technical solutions aimed at increasing production yields by managing defective interfering particles (DIPs).

Founded in 2019, the biotechnology firm focuses on improving manufacturing efficiency for both established and developing live attenuated and inactivated viral vaccines. Its initial commercial focus is the flu vaccine market. The platform is designed to reduce the generation of DIPs during all stages of manufacture without requiring significant changes to existing production processes or regulatory compliance frameworks.

The latest funding (allotted in April 2026) follows a series of previous capital raises. In April 2025, the company completed two allotments totaling approximately £138.7k. Other previous rounds include £94.1k in December 2024, £150k in May 2024, and £37.5k in March 2024. Earlier funding history includes a £274.6k round in March 2023 and three separate allotments in 2021 totaling £250.2k.

Financial records for the company show a workforce of 10 employees, while recent LinkedIn data indicates a headcount of seven. The most recent accounts report a loss of £779.

Ovo Biomanufacturing positions its technology as a solution to a specific bottleneck in vaccine production. By minimizing the impact of defective particles, the platform aims to maximize the volume of target viruses produced by manufacturers. The company operates within the research and experimental development sector of biotechnology.